Peak ProcessingASX:PKP 3-Year RORE % is -34.19 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 938 Drug Manufacturers companies, Peak Processing ranks worse than 75.05% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Peak Processing's 3-Year RORE % for the quarter that ended in Dec. 2025 was -34.19%.
The industry rank for Peak Processing's 3-Year RORE % or its related term are showing as below:
ASX:PKP's 3-Year RORE % is ranked worse than 75.05% of 938
companies
in the Drug Manufacturers industry
Industry Median: 3.075
vs ASX:PKP: -34.19
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Peak Processing 3-Year RORE % Related Terms
Peak Processing 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Peak Processing's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Peak Processing's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peak Processing 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Peak Processing's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Peak Processing's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Peak Processing (ASX:PKP) has a 3-Year RORE % of -34.19 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Peak Processing and its competitors. According to the industry distribution chart, Peak Processing ranks #704 out of 938 companies in the Drug Manufacturers industry, placing it in the top 75.1%.
Is Peak Processing's 3-Year RORE % too high?
Peak Processing's current 3-Year RORE % is -34.19. Based on the distribution chart, Peak Processing ranks #704 out of 938 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Peak Processing's 3-Year RORE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peak Processing ranks #704 out of 938 companies for 3-Year RORE %. This places Peak Processing in the lower half of its industry. The industry median 3-Year RORE % is 3.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.08, based on 938 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Peak Processing and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peak Processing's current 3-Year RORE % is -34.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peak Processing stock overvalued right now?
Based on GuruFocus' analysis, Peak Processing (ASX:PKP) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.02 — trading 70% above its estimated fair value. The current 3-Year RORE % is -34.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Peak Processing (ASX:PKP), the current 3-Year RORE % is -34.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peak Processing Ltd is engaged in the manufacturing, sales, and distribution of cannabis-based medicines and recreational cannabis products. The products of the company includes cannabis-infused beverage, Hydrocarbon Extracts, oils, vapes, topicals, powder, infused flowers, and others. The company is also engaged in manufacturing services for cannabis products and blending and mixing, bulk filling, packaging, labelling and lab testing work.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PKP has been successfully added to your 